{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:16:04Z","timestamp":1793924164778,"version":"4.8.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In Alzheimer\u2019s disease (AD), tau pathology is more strongly linked to neurodegeneration than amyloid-\u03b2 and better predicts brain atrophy. The spatial extent of tauopathy (SEOT) has shown promise as an earlier and more sensitive marker of AD severity than tau load, but how these complementary dimensions relate to neurodegeneration remains unclear. Here, we compared the in vivo associations of tau-PET extent versus load with cross-sectional and longitudinal neurodegeneration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We studied 367 participants across the healthy-aging to AD continuum (mean age 69.3\u2009years; 61% female) from the TRIAD cohort who underwent [\n                      <jats:sup>18<\/jats:sup>\n                      F]MK-6240 tau-PET. Tau load was quantified as regional standardized uptake value ratio (SUVR), and SEOT as the proportion of abnormal voxels, within a temporal meta-region of interest (ROI) and a full-cortex ROI. Neurodegeneration markers included cortical thickness, hippocampal volume (HCV), medial temporal atrophy (MTA) visual ratings, plasma neurofilament light (NfL), and CSF total tau (t-tau). Cross-sectional associations were evaluated using multiple linear regression or covariate-adjusted Spearman correlations. We also compared local correlations of tau load and extent with cortical thickness across all cortical regions. Longitudinal predictive value for neurodegeneration was tested using linear mixed-effects models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Cross-sectionally, all tau-PET metrics were significantly associated with neurodegeneration across imaging and fluid biomarkers. Full-cortex SEOT provided the best model fit for cortical thinning. SEOT outperformed tau load for associations with HCV and for predicting MTA, whereas SEOT and SUVR showed comparable associations with plasma NfL and CSF t-tau. Tau extent was equal or superior to tau load in its correlation with local cortical thickness across all cortical regions. Longitudinally, baseline full-cortex SEOT best predicted future cortical thinning, while temporal SEOT best predicted future hippocampal atrophy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Across cross-sectional and longitudinal analyses, tau extent provided superior predictive value for imaging-based neurodegeneration compared with tau load. By enabling a spatially unbiased, whole-brain assessment of tau burden that accommodates heterogeneous topographies, SEOT represents a promising complementary tau-PET metric for staging and tracking disease progression in AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13024-026-00945-1","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:35:02Z","timestamp":1780572902000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tau extent outperforms tau load as a predictor of neurodegeneration in Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"21","author":[{"given":"Arthur C.","family":"Macedo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Trudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyyed Ali","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Therriault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9tienne","family":"Aumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gleb","family":"Bezgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrine","family":"Rahmouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Tissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel S.","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn","family":"Servaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Fernandez-Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tevy","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Pereira","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela C. L.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Pedro","family":"Ferrari-Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"Bellaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firoza Z.","family":"Lussier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9a L.","family":"Benedet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana L.","family":"Tudorascu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo R.","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Montembeault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Soucy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Klostranec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tharick A.","family":"Pascoal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Vitali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Rosa-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"2","key":"945_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr","year":"2013","unstructured":"Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. The Lancet Neurol. 2013;12(2):207\u201316. https:\/\/doi.org\/10.1016\/S1474-4422(12)70291-0.","journal-title":"The Lancet Neurol"},{"issue":"1","key":"945_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00401-009-0532-1","volume":"118","author":"C Duyckaerts","year":"2009","unstructured":"Duyckaerts C, Delatour B, Potier MC. Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 2009;118(1):5\u201336. https:\/\/doi.org\/10.1007\/s00401-009-0532-1.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"945_CR3","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1212\/WNL.0000000000002892","volume":"87","author":"H Cho","year":"2016","unstructured":"Cho H, Choi JY, Hwang MS, Lee JH, Kim YJ, Lee HMLyoo CH, et al. Tau PET in Alzheimer disease and mild cognitive impairment. Neurology. 2016;87(4):375\u201383. https:\/\/doi.org\/10.1212\/WNL.0000000000002892.","journal-title":"Neurology"},{"key":"945_CR4","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.nicl.2017.09.016","volume":"17","author":"L Iaccarino","year":"2018","unstructured":"Iaccarino L, Tammewar G, Ayakta N, Baker SL, Bejanin A, Boxer AL, et al. Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer\u2019s disease. NeuroImage. Clin. 2018;17:452\u201364. https:\/\/doi.org\/10.1016\/j.nicl.2017.09.016.","journal-title":"NeuroImage. Clin"},{"issue":"2","key":"945_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2967\/jnumed.117.194282","volume":"59","author":"IM Nasrallah","year":"2018","unstructured":"Nasrallah IM, Chen YJ, Hsieh MK, Phillips JS, Ternes K, Stockbower GE, et al. 18F-Flortaucipir PET\/MRI correlations in Nonamnestic and amnestic variants of Alzheimer disease. J Nucl Med. 2018, Feb;59(2):299\u2013306. https:\/\/doi.org\/10.2967\/jnumed.117.194282.","journal-title":"J Nucl Med"},{"issue":"5","key":"945_CR6","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele R, Schonhaut DR, Sch\u00f6ll M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain. 2016, May;139(5):1551\u201367. https:\/\/doi.org\/10.1093\/brain\/aww027.","journal-title":"Brain"},{"issue":"2","key":"945_CR7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3233\/JAD-160316","volume":"55","author":"J Dronse","year":"2016","unstructured":"Dronse J, Fliessbach K, Bischof GN, von Reutern B, Faber J, Hammes J, et al. In vivo patterns of tau pathology, amyloid-\u03b2 burden, and neuronal dysfunction in clinical variants of Alzheimer\u2019s disease. JAD. 2016;55(2):465\u201371. https:\/\/doi.org\/10.3233\/JAD-160316.","journal-title":"JAD"},{"key":"945_CR8","doi-asserted-by":"publisher","unstructured":"La Joie R, Visani AV, Baker SL, Brown JA, Bourakova V, Cha J, et al. Prospective longitudinal atrophy in Alzheimer\u2019s disease correlates with the intensity and topography of baseline tau-PET. Sci Transl Med. 2020, Jan, 1;12(524):eaau5732. https:\/\/doi.org\/10.1126\/scitranslmed.aau5732.","DOI":"10.1126\/scitranslmed.aau5732"},{"key":"945_CR9","doi-asserted-by":"publisher","first-page":"105080","DOI":"10.1016\/j.ebiom.2024.105080","volume":"103","author":"S Doering","year":"2024","unstructured":"Doering S, McCullough A, Gordon BA, Chen CD, McKay N, Hobbs D, et al. Deconstructing pathological tau by biological process in early stages of Alzheimer disease: a method for quantifying tau spatial spread in neuroimaging. EBioMedicine. 2024, May;103:105080. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105080.","journal-title":"EBioMedicine"},{"issue":"6","key":"945_CR10","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1007\/s00259-024-06603-2","volume":"51","author":"T G\u00e9rard","year":"2024","unstructured":"G\u00e9rard T, Colmant L, Malotaux V, Salman Y, Huyghe L, Quenon L, et al. The spatial extent of tauopathy on [18F]MK-6240 tau PET shows stronger association with cognitive performances than the standard uptake value ratio in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imag. 2024, May;51(6):1662\u201374. https:\/\/doi.org\/10.1007\/s00259-024-06603-2.","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"945_CR11","doi-asserted-by":"publisher","unstructured":"Macedo AC, Trudel L, Therriault J, Rahmouni N, Aumont E, Bezgin G, et al. Spatiotemporal dynamics of tau extent and load increase in Alzheimer's disease across four longitudinal cohorts. Nat Aging. In press. https:\/\/doi.org\/10.1038\/s43587-026-01143-w.","DOI":"10.1038\/s43587-026-01143-w"},{"issue":"4","key":"945_CR12","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1001\/jamaneurol.2019.4421","volume":"77","author":"J Therriault","year":"2020","unstructured":"Therriault J, Benedet AL, Pascoal TA, Mathotaarachchi S, Chamoun M, Savard M, et al. Association of apolipoprotein E \u03b54 with medial temporal tau independent of amyloid-\u03b2. JAMA Neurol. 2020, Apr, 1;77(4):470\u201379. https:\/\/doi.org\/10.1001\/jamaneurol.2019.4421.","journal-title":"JAMA Neurol"},{"issue":"5","key":"945_CR13","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/brain\/awy059","volume":"141","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Wiste HJ, Schwarz CG, Lowe VJ, Senjem ML, Vemuri P, et al. Longitudinal tau PET in ageing and Alzheimer\u2019s disease. Brain. 2018, May, 1;141(5):1517\u201328. https:\/\/doi.org\/10.1093\/brain\/awy059.","journal-title":"Brain"},{"issue":"3","key":"945_CR14","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers & Dementia. 2011, May;7(3):270\u201379. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.008.","journal-title":"Alzheimers & Dementia"},{"issue":"3","key":"945_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers & Dementia. 2011, May;7(3):263\u201369. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005.","journal-title":"Alzheimers & Dementia"},{"issue":"12","key":"945_CR16","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1093\/brain\/awaa342","volume":"143","author":"AL Benedet","year":"2020","unstructured":"Benedet AL, Leuzy A, Pascoal TA, Ashton NJ, Mathotaarachchi S, Savard M, et al. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer\u2019s disease. Brain. 2020, Dec, 1;143(12):3793\u2013804. https:\/\/doi.org\/10.1093\/brain\/awaa342.","journal-title":"Brain"},{"issue":"2","key":"945_CR17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1515\/cclm-2021-0651","volume":"60","author":"J Gobom","year":"2022","unstructured":"Gobom J, Parnetti L, Rosa-Neto P, Vyhnalek M, Gauthier S, Cataldi S, et al. Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. Clin Chem Lab Med (CCLM). 2022, Nov, 15;60(2):207\u201319. https:\/\/doi.org\/10.1515\/cclm-2021-0651.","journal-title":"Clin Chem Lab Med (CCLM)"},{"key":"945_CR18","doi-asserted-by":"publisher","unstructured":"Wu L, Rowley J, Mohades S, Leuzy A, Dauar MT, Shin M, et al. Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment. PLoS One. 2012;7(10):e47905. https:\/\/doi.org\/10.1371\/journal.pone.0047905.","DOI":"10.1371\/journal.pone.0047905"},{"key":"945_CR19","doi-asserted-by":"publisher","unstructured":"Aumont E, Hall BJ, Chan T, Trudel L, Bezgin G, Hosseini SA, et al. Optimized atlas for early tau-PET staging via native space segmentations. Prepr Posted To SSRN. 2025, Jan. https:\/\/doi.org\/10.2139\/ssrn.5204665.","DOI":"10.2139\/ssrn.5204665"},{"issue":"9","key":"945_CR20","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1093\/brain\/awaa180","volume":"143","author":"TA Pascoal","year":"2020","unstructured":"Pascoal TA, Therriault J, Benedet AL, Savard M, Lussier FZ, Chamoun M, et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain. 2020, Sep, 1;143(9):2818\u201330. https:\/\/doi.org\/10.1093\/brain\/awaa180.","journal-title":"Brain"},{"issue":"4","key":"945_CR21","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/j.neuroimage.2012.02.084","volume":"61","author":"M Reuter","year":"2012","unstructured":"Reuter M, Schmansky NJ, Rosas HD, Fischl B. Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage. 2012, Jul, 16;61(4):1402\u201318. https:\/\/doi.org\/10.1016\/j.neuroimage.2012.02.084.","journal-title":"Neuroimage"},{"issue":"3","key":"945_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","volume":"13","author":"CR Jack Jr","year":"2017","unstructured":"Jack CR Jr, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, et al. Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease. Alzheimers & Dementia. 2017, Mar;13(3):205\u201316. https:\/\/doi.org\/10.1016\/j.jalz.2016.08.005.","journal-title":"Alzheimers & Dementia"},{"issue":"11","key":"945_CR23","doi-asserted-by":"publisher","first-page":"8074","DOI":"10.1002\/alz.14315","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler SE, Petersen KK, Saef B, Tosun D, Shaw LM, Zetterberg H, et al. Head-to-head comparison of leading blood tests for Alzheimer\u2019s disease pathology. Alzheimers & Dementia. 2024, Nov;20(11):8074\u201396. https:\/\/doi.org\/10.1002\/alz.14315.","journal-title":"Alzheimers & Dementia"},{"issue":"1","key":"945_CR24","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/hbm.22627","volume":"36","author":"PA Yushkevich","year":"2015","unstructured":"Yushkevich PA, Pluta JB, Wang H, Xie L, Ding SL, Gertje EC, et al. Automated volumetry and regional thickness analysis of hippocampal subfields and medial temporal cortical structures in mild cognitive impairment. Hum Brain Mapp. 2015, Jan;36(1):258\u201387. https:\/\/doi.org\/10.1002\/hbm.22627.","journal-title":"Hum Brain Mapp"},{"issue":"9","key":"945_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/BF00868807","volume":"242","author":"P Scheltens","year":"1995","unstructured":"Scheltens P, Launer LJ, Barkhof F, Weinstein HC, van Gool WA. Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. J Neurol. 1995, Sep;242(9):557\u201360. https:\/\/doi.org\/10.1007\/BF00868807.","journal-title":"J Neurol"},{"issue":"8","key":"945_CR26","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1007\/s00330-016-4726-3","volume":"27","author":"JJ Claus","year":"2017","unstructured":"Claus JJ, Staekenborg SS, Holl DC, Roorda JJ, Schuur J, Koster P, et al. Practical use of visual medial temporal lobe atrophy cut-off scores in Alzheimer\u2019s disease: validation in a large memory clinic population. Eur Radiol. 2017, Aug;27(8):3147\u201355. https:\/\/doi.org\/10.1007\/s00330-016-4726-3.","journal-title":"Eur Radiol"},{"issue":"4","key":"945_CR27","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00234-019-02156-6","volume":"61","author":"C H\u00e5kansson","year":"2019","unstructured":"H\u00e5kansson C, Torisson G, Londos E, Hansson O, van Westen D. Structural imaging findings on non-enhanced computed tomography are severely underreported in the primary care diagnostic work-up of subjective cognitive decline. Neuroradiology. 2019, Apr;61(4):397\u2013404. https:\/\/doi.org\/10.1007\/s00234-019-02156-6.","journal-title":"Neuroradiology"},{"issue":"3","key":"945_CR28","doi-asserted-by":"publisher","first-page":"452","DOI":"10.2967\/jnumed.122.264434","volume":"64","author":"C Tissot","year":"2023","unstructured":"Tissot C, Servaes S, Lussier FZ, Ferrari-Souza JP, Therriault J, Ferreira PCL, et al. The Association of age-related and off-Target retention with longitudinal quantification of [18F]MK6240 tau PET in Target regions. J Nucl Med. 2023, Mar;64(3):452\u201359. https:\/\/doi.org\/10.2967\/jnumed.122.264434.","journal-title":"J Nucl Med"},{"issue":"6","key":"945_CR29","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s43587-022-00204-0","volume":"2","author":"J Therriault","year":"2022","unstructured":"Therriault J, Pascoal TA, Lussier FZ, Tissot C, Chamoun M, Bezgin G, et al. Biomarker modeling of Alzheimer\u2019s disease using PET-based Braak staging. Nat Aging. 2022, Jun;2(6):526\u201335. https:\/\/doi.org\/10.1038\/s43587-022-00204-0.","journal-title":"Nat Aging"},{"key":"945_CR30","doi-asserted-by":"publisher","unstructured":"Macedo AC, Therriault J, Tissot C, Fernandez-Arias J, Ferreira PCL, Vitali P, et al. Predicting functional decline in aging and Alzheimer\u2019s disease with PET-based Braak staging. Brain Commun. 2024, Feb, 26;6(2):fcae043. https:\/\/doi.org\/10.1093\/braincomms\/fcae043.","DOI":"10.1093\/braincomms\/fcae043"},{"key":"945_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.neurobiolaging.2024.09.009","volume":"144","author":"AC Macedo","year":"2024","unstructured":"Macedo AC, Therriault J, Tissot C, Aumont \u00c9, Servaes S, Rahmouni N, et al. Modeling the progression of neuropsychiatric symptoms in Alzheimer\u2019s disease with PET-based Braak staging. Neurobiol Aging. 2024, Dec;144:127\u201337. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2024.09.009.","journal-title":"Neurobiol Aging"},{"key":"945_CR32","doi-asserted-by":"publisher","unstructured":"Doering E, Hoenig MC, Giehl K, Dzialas V, Andrassy G, Bader A, et al. \u201cFill States\u201d: PET-derived markers of the spatial extent of Alzheimer disease pathology. Radiology. 2025, Mar;314(3):e241482. https:\/\/doi.org\/10.1148\/radiol.241482.","DOI":"10.1148\/radiol.241482"},{"issue":"4","key":"945_CR33","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/brain\/awad397","volume":"147","author":"YT Wang","year":"2024","unstructured":"Wang YT, Therriault J, Servaes S, Tissot C, Rahmouni N, Macedo AC, et al. Sex-specific modulation of amyloid-\u03b2 on tau phosphorylation underlies faster tangle accumulation in females. Brain. 2024, Apr, 4;147(4):1497\u2013510. https:\/\/doi.org\/10.1093\/brain\/awad397.","journal-title":"Brain"},{"key":"945_CR34","doi-asserted-by":"publisher","unstructured":"Therriault J, Pascoal TA, Benedet AL, Tissot C, Savard M, Chamoun M, et al. Frequency of biologically defined Alzheimer disease in relation to age, sex, APOE \u03b54, and cognitive impairment. Neurology. 2021, Feb, 16;96(7):e975\u201385. https:\/\/doi.org\/10.1212\/WNL.0000000000011416.","DOI":"10.1212\/WNL.0000000000011416"},{"issue":"13","key":"945_CR35","doi-asserted-by":"publisher","first-page":"5135","DOI":"10.1007\/s00259-025-07384-y","volume":"52","author":"EM Coomans","year":"2025","unstructured":"Coomans EM, van Tol B, Groot C, Smith R, Palmqvist S, Stomrud E, et al. Quantitation of PET spatial extent as a potential adjunct to visual interpretation of [18F]flortaucipir imaging: TAU-SPEX. Eur J Nucl Med Mol Imag. 2025, Jun, 7;52(13):5135\u201349. https:\/\/doi.org\/10.1007\/s00259-025-07384-y.","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"2","key":"945_CR36","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2967\/jnumed.120.245209","volume":"62","author":"J Therriault","year":"2021","unstructured":"Therriault J, Benedet AL, Pascoal TA, Savard M, Ashton NJ, Chamoun M, et al. Determining amyloid-\u03b2 positivity using 18F-AZD4694 PET imaging. J Nucl Med. 2021, Feb;62(2):247\u201352. https:\/\/doi.org\/10.2967\/jnumed.120.245209.","journal-title":"J Nucl Med"},{"key":"945_CR37","doi-asserted-by":"publisher","unstructured":"Cavanaugh JE, Neath AA. The Akaike information criterion: background, derivation, properties, application, interpretation, and refinements. WIREs Comput Stats. 2019;11(3):e1460. https:\/\/doi.org\/10.1002\/wics.1460.","DOI":"10.1002\/wics.1460"},{"issue":"2","key":"945_CR38","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/0049124104268644","volume":"33","author":"KP Burnham","year":"2004","unstructured":"Burnham KP, Anderson DR. Multimodel inference: understanding AIC and BIC in model selection. Sociol Method Res. 2004;33(2):261\u2013304. https:\/\/doi.org\/10.1177\/0049124104268644.","journal-title":"Sociol Method Res"},{"key":"945_CR39","doi-asserted-by":"publisher","unstructured":"Diedenhofen B, Musch J. Cocor: a comprehensive solution for the statistical comparison of correlations. PLoS One. 2015;10(4):e0121945. https:\/\/doi.org\/10.1371\/journal.pone.0121945.","DOI":"10.1371\/journal.pone.0121945"},{"issue":"3","key":"945_CR40","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.neuroimage.2006.01.021","volume":"31","author":"RS Desikan","year":"2006","unstructured":"Desikan RS, S\u00e9gonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006, Jul, 1;31(3):968\u201380. https:\/\/doi.org\/10.1016\/j.neuroimage.2006.01.021.","journal-title":"Neuroimage"},{"key":"945_CR41","doi-asserted-by":"publisher","unstructured":"St-Onge F, Chapleau M, Breitner JCS, Villeneuve S, Pichet Binette A. Tau accumulation and its spatial progression across the Alzheimer\u2019s disease spectrum. Brain Commun. 2023, Feb, 7;6(1):fcae031. https:\/\/doi.org\/10.1093\/braincomms\/fcae031.","DOI":"10.1093\/braincomms\/fcae031"},{"issue":"8","key":"945_CR42","doi-asserted-by":"publisher","first-page":"5434","DOI":"10.1002\/alz.14036","volume":"20","author":"ME Farrell","year":"2024","unstructured":"Farrell ME, Thibault EG, Becker JA, Price JC, Healy BC, Hanseeuw BJ, et al. Spatial extent as a sensitive amyloid-PET metric in preclinical Alzheimer\u2019s disease. Alzheimers & Dementia. 2024, Aug;20(8):5434\u201349. https:\/\/doi.org\/10.1002\/alz.14036.","journal-title":"Alzheimers & Dementia"},{"issue":"10","key":"945_CR43","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/jamaneurol.2022.2442","volume":"79","author":"H Ozlen","year":"2022","unstructured":"Ozlen H, Pichet Binette A, K\u00f6be T, Meyer PF, Gonneaud J, St-Onge F, et al. Spatial extent of amyloid-\u03b2 levels and associations with tau-PET and cognition. JAMA Neurol. 2022, Oct, 1;79(10):1025\u201335. https:\/\/doi.org\/10.1001\/jamaneurol.2022.2442.","journal-title":"JAMA Neurol"},{"key":"945_CR44","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.neurobiolaging.2024.11.007","volume":"146","author":"E Aumont","year":"2025","unstructured":"Aumont E, Bedard MA, Bussy A, Arias JF, Tissot C, Hall BJ, et al. Hippocampal atrophy over two years in relation to tau, amyloid-\u03b2 and memory in older adults. Neurobiol Aging. 2025, Feb;146:48\u201357. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2024.11.007.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"945_CR45","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40035-024-00432-x","volume":"13","author":"E Liu","year":"2024","unstructured":"Liu E, Zhang Y, Wang JZ. Updates in Alzheimer\u2019s disease: from basic research to diagnosis and therapies. Transl Neurodegener. 2024, Sep, 4;13(1):45. https:\/\/doi.org\/10.1186\/s40035-024-00432-x.","journal-title":"Transl Neurodegener"},{"issue":"12","key":"945_CR46","doi-asserted-by":"publisher","first-page":"5562","DOI":"10.1073\/pnas.91.12.5562","volume":"91","author":"AC Alonso","year":"1994","unstructured":"Alonso AC, Zaidi T, Grundke-Iqbal I, Iqbal K. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci USA. 1994, Jun, 7;91(12):5562\u201366. https:\/\/doi.org\/10.1073\/pnas.91.12.5562.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"945_CR47","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00401-015-1507-z","volume":"131","author":"J Lewis","year":"2016","unstructured":"Lewis J, Dickson DW. Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol. 2016, Jan;131(1):27\u201348. https:\/\/doi.org\/10.1007\/s00401-015-1507-z.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"945_CR48","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.biopsych.2017.04.003","volume":"83","author":"JI Ayers","year":"2018","unstructured":"Ayers JI, Giasson BI, Borchelt DR. Prion-like spreading in Tauopathies. Biol Psychiatry. 2018, Feb, 15;83(4):337\u201346. https:\/\/doi.org\/10.1016\/j.biopsych.2017.04.003.","journal-title":"Biol Psychiatry"},{"issue":"32","key":"945_CR49","doi-asserted-by":"publisher","first-page":"24374","DOI":"10.1016\/S0021-9258(20)80536-5","volume":"268","author":"E K\u00f6pke","year":"1993","unstructured":"K\u00f6pke E, Tung YC, Shaikh S, Alonso AC, Iqbal K, Grundke-Iqbal I. Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem. 1993, Nov, 15;268(32):24374\u201384. https:\/\/doi.org\/10.1016\/S0021-9258(20)80536-5.","journal-title":"J Biol Chem"},{"issue":"12","key":"945_CR50","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3389\/fnins.2018.00267","volume":"12","author":"SL DeVos","year":"2018","unstructured":"DeVos SL, Corjuc BT, Oakley DH, Nobuhara CK, Bannon RN, Chase A, et al. Synaptic tau seeding precedes tau pathology in human Alzheimer\u2019s disease brain. Front. Neurosci. 2018, Apr;12(12):267. https:\/\/doi.org\/10.3389\/fnins.2018.00267.","journal-title":"Front. Neurosci"},{"issue":"1","key":"945_CR51","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s40478-021-01255-x","volume":"9","author":"BE Stopschinski","year":"2021","unstructured":"Stopschinski BE, Del Tredici K, Estill-Terpack SJ, Ghebremedhin E, Yu FF, Braak H, et al. Anatomic survey of seeding in Alzheimer\u2019s disease brains reveals unexpected patterns. Acta Neuropathol Commun. 2021, Oct, 11;9(1):164. https:\/\/doi.org\/10.1186\/s40478-021-01255-x.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"945_CR52","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00401-023-02574-0","volume":"146","author":"M Manca","year":"2023","unstructured":"Manca M, Standke HG, Browne DF, Huntley ML, Thomas OR, Orr\u00fa CD, et al. Tau seeds occur before earliest Alzheimer\u2019s changes and are prevalent across neurodegenerative diseases. Acta Neuropathol. 2023, Jul;146(1):31\u201350. https:\/\/doi.org\/10.1007\/s00401-023-02574-0.","journal-title":"Acta Neuropathol"},{"issue":"3","key":"945_CR53","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jalz.2019.09.079","volume":"16","author":"VJ Lowe","year":"2020","unstructured":"Lowe VJ, Lundt ES, Albertson SM, Min HK, Fang P, Przybelski SA, et al. Tau-positron emission tomography correlates with neuropathology findings. Alzheimers & Dementia. 2020, Mar;16(3):561\u201371. https:\/\/doi.org\/10.1016\/j.jalz.2019.09.079.","journal-title":"Alzheimers & Dementia"},{"issue":"4","key":"945_CR54","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","volume":"112","author":"H Braak","year":"2006","unstructured":"Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006, Oct;112(4):389\u2013404. https:\/\/doi.org\/10.1007\/s00401-006-0127-z.","journal-title":"Acta Neuropathol"},{"issue":"8","key":"945_CR55","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2967\/jnumed.122.265200","volume":"64","author":"AC Macedo","year":"2023","unstructured":"Macedo AC, Tissot C, Therriault J, Servaes S, Wang YT, Fernandez-Arias J, et al. The use of tau PET to Stage Alzheimer disease according to the Braak staging Framework. J Nucl Med. 2023, Aug;64(8):1171\u201378. https:\/\/doi.org\/10.2967\/jnumed.122.265200.","journal-title":"J Nucl Med"},{"issue":"1","key":"945_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging\u2013Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers & Dementia. 2012, Jan;8(1):1\u201313. https:\/\/doi.org\/10.1016\/j.jalz.2011.10.007.","journal-title":"Alzheimers & Dementia"},{"issue":"4","key":"945_CR57","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00401-019-02036-6","volume":"138","author":"C Petersen","year":"2019","unstructured":"Petersen C, Nolan AL, de Paula Fran\u00e7a Resende E, Miller Z, Ehrenberg AJ, Gorno-Tempini ML, et al. Alzheimer\u2019s disease clinical variants show distinct regional patterns of neurofibrillary tangle accumulation. Acta Neuropathol. 2019, Oct;138(4):597\u2013612. https:\/\/doi.org\/10.1007\/s00401-019-02036-6.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"945_CR58","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40478-016-0315-6","volume":"4","author":"VJ Lowe","year":"2016","unstructured":"Lowe VJ, Curran G, Fang P, Liesinger AM, Josephs KA, Parisi JE, et al. An autoradiographic evaluation of AV-1451 tau PET in dementia. Acta Neuropathol Commun. 2016, Jun, 13;4(1):58. https:\/\/doi.org\/10.1186\/s40478-016-0315-6.","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"945_CR59","doi-asserted-by":"publisher","first-page":"414","DOI":"10.14283\/jpad.2024.15","volume":"11","author":"AC Macedo","year":"2024","unstructured":"Macedo AC, Dur\u00e7o DFPA, Tissot C, Therriault J, Vilela de Faria AO, Aumont \u00c9, et al. Clinical correlates of the PET-based Braak staging Framework in Alzheimer\u2019s disease. J Sport Hist Prev Alzheimers Disease. 2024;11(2):414\u201321. https:\/\/doi.org\/10.14283\/jpad.2024.15.","journal-title":"J Sport Hist Prev Alzheimers Disease"},{"issue":"5","key":"945_CR60","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41591-021-01309-6","volume":"27","author":"JW Vogel","year":"2021","unstructured":"Vogel JW, Young AL, Oxtoby NP, Smith R, Ossenkoppele R, Strandberg OT, et al. Four distinct trajectories of tau deposition identified in Alzheimer\u2019s disease. Nat Med. 2021, May;27(5):871\u201381. https:\/\/doi.org\/10.1038\/s41591-021-01309-6.","journal-title":"Nat Med"},{"key":"945_CR61","doi-asserted-by":"publisher","unstructured":"Therriault J, Pascoal TA, Savard M, Benedet AL, Chamoun M, Tissot C, et al. Topographic distribution of amyloid-\u03b2, tau, and atrophy in patients with Behavioral\/Dysexecutive Alzheimer disease. Neurology. 2021, Jan, 5;96(1):e81\u201392. https:\/\/doi.org\/10.1212\/WNL.0000000000011081.","DOI":"10.1212\/WNL.0000000000011081"},{"issue":"157","key":"945_CR62","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.neuroimage.2017.05.058","volume":"157","author":"A Maass","year":"2017","unstructured":"Maass A, Landau S, Baker SL, Horng A, Lockhart SN, La Joie R, et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer\u2019s disease. Neuroimage. 2017, Aug;157(157):448\u201363. https:\/\/doi.org\/10.1016\/j.neuroimage.2017.05.058.","journal-title":"Neuroimage"},{"issue":"8","key":"945_CR63","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers & Dementia. 2024, Aug;20(8):5143\u201369. https:\/\/doi.org\/10.1002\/alz.13859.","journal-title":"Alzheimers & Dementia"},{"issue":"1","key":"945_CR64","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13024-021-00430-x","volume":"16","author":"H Zetterberg","year":"2021","unstructured":"Zetterberg H, Blennow K. Moving fluid biomarkers for Alzheimer\u2019s disease from research tools to routine clinical diagnostics. Mol Neurodegener. 2021, Feb, 19;16(1):10. https:\/\/doi.org\/10.1186\/s13024-021-00430-x.","journal-title":"Mol Neurodegener"},{"issue":"9","key":"945_CR65","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1111\/ene.15428","volume":"29","author":"I Kmezic","year":"2022","unstructured":"Kmezic I, Samuelsson K, Finn A, Upate Z, Blennow K, Zetterberg H, et al. Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies. Euro J Neurol. 2022, Sep;29(9):2810\u201322. https:\/\/doi.org\/10.1111\/ene.15428.","journal-title":"Euro J Neurol"},{"key":"945_CR66","doi-asserted-by":"publisher","unstructured":"Nichols E, Merrick R, Hay SI, Himali D, Himali JJ, Hunter S, et al. The prevalence, correlation, and co-occurrence of neuropathology in old age: harmonisation of 12 measures across six community-based autopsy studies of dementia. LancetThe Lancet Healthy Longevity. 2023, Mar;4(3):e115\u201325. https:\/\/doi.org\/10.1016\/S2666-7568(23)00019-3.","DOI":"10.1016\/S2666-7568(23)00019-3"},{"issue":"12","key":"945_CR67","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/S1474-4422(25)00350-3","volume":"24","author":"CR Jack Jr","year":"2025","unstructured":"Jack CR Jr, Hu M, Wiste HJ, Knopman DS, Vemuri P, Graff-Radford JLowe VJ, et al. Lifetime and 10-year absolute risk of cognitive impairment in relation to amyloid PET severity: a retrospective, longitudinal cohort study. The Lancet Neurol. 2025, Dec;24(12):1016\u201325. https:\/\/doi.org\/10.1016\/S1474-4422(25)00350-3.","journal-title":"The Lancet Neurol"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-026-00945-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-026-00945-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-026-00945-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:02:25Z","timestamp":1786532545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13024-026-00945-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["945"],"URL":"https:\/\/doi.org\/10.1186\/s13024-026-00945-1","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The TRIAD study received ethical approval from the Montreal Neurological Institute (MNI) PET Working Committee and the Douglas Mental Health University Institute Research Ethics Board (IUSMD 16\u201360). All participants signed informed consent forms after being explained about all research procedures.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JT has served as a consultant for the Neurotorium educational platform, outside of the scope of the submitted work. MSW receives honoraria from Lilly and EIsai for lectures outside the scope of this manuscript. HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merck Sharp & Dohme, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, ScandiBio Therapeutics AB, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, LabCorp, Lilly, Novo Nordisk, Oy Medix Biochemica AB, Roche, and WebMD, is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, and is a shareholder of MicThera (outside submitted work). ERZ has served on the scientific advisory board, as a consultant or speaker for Nintx, Novo Nordisk, Biogen, Lilly, Magdalena Biosciences and masima. He is also a co-founder and minority shareholder of masima. Outside the work presented in this paper, PRN provides consultancy services for Roche, Cerveau Radiopharmaceuticals, Lilly, Eisai, Pfizer, and Novo Nordisk. PRN also serves as a clinical trials investigator for Biogen, Novo Nordisk, and Biogen.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"45"}}